Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E24.95 EPS (ttm)2.54 Insider Own0.10% Shs Outstand1.64B Perf Week5.86%
Market Cap103.96B Forward P/E19.73 EPS next Y3.22 Insider Trans-8.96% Shs Float1.63B Perf Month3.64%
Income4.23B PEG2.32 EPS next Q0.67 Inst Own71.40% Short Float0.49% Perf Quarter-1.54%
Sales20.57B P/S5.05 EPS this Y184.60% Inst Trans0.05% Short Ratio1.40 Perf Half Y14.08%
Book/sh9.02 P/B7.03 EPS next Y7.27% ROA12.60% Target Price64.23 Perf Year26.86%
Cash/sh4.35 P/C14.60 EPS next 5Y10.75% ROE28.20% 52W Range46.01 - 66.10 Perf YTD3.51%
Dividend1.60 P/FCF63.08 EPS past 5Y4.20% ROI19.80% 52W High-4.04% Beta1.08
Dividend %2.52% Quick Ratio1.50 Sales past 5Y-1.80% Gross Margin72.60% 52W Low37.86% ATR1.08
Employees25000 Current Ratio1.60 Sales Q/Q6.70% Oper. Margin27.30% RSI (14)60.24 Volatility1.85% 1.55%
OptionableYes Debt/Eq0.57 EPS Q/Q-28.20% Profit Margin20.60% Rel Volume1.04 Prev Close63.28
ShortableYes LT Debt/Eq0.47 EarningsFeb 05 BMO Payout60.70% Avg Volume5.68M Price63.43
Recom2.40 SMA202.72% SMA502.50% SMA2007.94% Volume5,888,607 Change0.24%
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Jan-23-18 03:39PM  How Is Novartiss Kymriah Positioned for 2018? Market Realist
11:37AM  Analysts Ratings for Nektar Therapeutics in January 2018 Market Realist
09:44AM  Seattle Genetics' Adcetris Gets EU Nod for Label Expansion Zacks
Jan-22-18 10:22AM  Bristol-Myers (BMY) Reports Data from CheckMate-142 Study Zacks
08:17AM  Whom Will Pfizer Buy in 2018? Motley Fool
07:32AM  Merck & Co.s Cardiovascular and Immunology Products in 3Q17 Market Realist
07:31AM  What Analysts Recommend for Bristol-Myers Squibb in January 2018 Market Realist
06:59AM  European Commission Approves Bristol-Myers Squibbs Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma Business Wire
Jan-21-18 12:25PM  Merck leaps past rivals with latest lung cancer drug results MarketWatch
Jan-20-18 02:03PM  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer Business Wire
Jan-19-18 03:17PM  BMY INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Bristol-Myers Squibb Company Investors Business Wire
11:05AM  Johnson & Johnsons Pharmaceutical Segment: 4Q17 Estimates Market Realist
10:34AM  Merck & Co.s Diabetes Products in 3Q17 Market Realist
10:32AM  Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb Market Realist
09:03AM  What to Expect from Bristol-Myers Squibbs Yervoy in 2018 Market Realist
09:01AM  Analysts Recommendations for Amgen in January 2018 Market Realist
08:05AM  Johnson & Johnsons 4Q17 Earnings on January 23: What to Expect Market Realist
08:02AM  Pharma And Biotech Dividend Stocks That Will Add Value To Your Portfolio Simply Wall St.
07:34AM  Keytruda: Merck & Co.s Immuno-Oncology Blockbuster Drug Market Realist
07:33AM  How Is Bristol-Myers Squibbs Sprycel Positioned for 2018? Market Realist
Jan-18-18 05:51PM  Bear Stearns Commercial Mortgage Securities Trust 2007-PWR15 -- Moody's Affirms Four Classes of BSCMS 2007-PWR15 Moody's
02:28PM  Mercks & Co.s Valuation in January 2018 Market Realist
11:30AM  Why Opdivo Could Continue to Be Growth Driver beyond 2018 Market Realist
11:24AM  Merck & Co., Inc. Stock Could Still Soar Another 10% From Here InvestorPlace
10:00AM  Opdivo Could Be Key Revenue Driver for Bristol-Myers Squibb in 2018 Market Realist
08:29AM  How Opdivo Is Positioned at the Beginning of 2018 Market Realist
Jan-17-18 02:08PM  The Case For Buying Bristol-Myers Squibb TheStreet.com
01:29PM  The Case For Bristol-Myers Squibb TheStreet.com
08:06AM  Exelixis, Ipsen Report Positive Results on Lead Cancer Drug Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Bristol-Myers Squibb Company and Merck & Co. ACCESSWIRE
07:34AM  Amgens Xgeva Could Witness Revenue Growth in 2018 Market Realist
Jan-16-18 04:44PM  Can Bristol-Myers Squibb Companys (NYSE:BMY) ROE Continue To Surpass The Industry Average? Simply Wall St.
12:01PM  Positive Keytruda lung cancer data sends Merck shares up 6 pct Reuters
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Jan-12-18 08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
07:32AM  Zelboraf Could Boost Roches Sales Growth in 2018 Market Realist
Jan-11-18 11:50AM  Mavyret May Prove a Strong Growth Driver for AbbVie Going Forward Market Realist
10:40AM  Trump looks to revamp major Medicaid requirements Yahoo Finance Video
09:04AM  TEVA Stock Price Rises on Generic Launch of Viread Market Realist
09:03AM  What to Expect from Roches Tecentriq and Avastin in 2018 Market Realist
09:02AM  How Mylans Rest of the World Segment Performed in 3Q17 Market Realist
08:38AM  Key Takeaways from Pfizer & 3 Other Drug Stocks at Healthcare Conference Zacks
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
07:34AM  Tevas Launch of Generic Version of Reyataz Boosts Stock Market Realist
Jan-10-18 04:40PM  What to Expect from Roches Investigational Drug Polatuzumab Vedotin Market Realist
11:07AM  Bayer and J&J win big, Microsoft lags because of Intel, Apple turns over information Yahoo Finance
10:43AM  Bayer and J&J win big, Microsoft lags because of Intel, Apple turns over information Yahoo Finance Video
10:33AM  AbbVies Rova-T: Can Label Expansion Make It a Blockbuster Drug? Market Realist
10:33AM  4 Reasons Exelixis, Inc. More Than Doubled in 2017 Motley Fool
09:05AM  AbbVies Rova-T and the Treatment of Small Cell Lung Cancer Market Realist
07:38AM  AbbVies Rova-T: Solid Growth Driver for the Future? Market Realist
07:37AM  Mylans Renaissance and Agila Acquisitions Market Realist
07:31AM  AbbVies Position in the Growing Oncology Market in 2018 Market Realist
Jan-09-18 05:15PM  AbbVie Rapidly Advancing Its 2018 Solid Tumor Portfolio Market Realist
03:35PM  What Mylan Expects for Fiscal 2017 Market Realist
02:05PM  Exploring Mylans Diversified Portfolio of Brands Market Realist
02:03PM  [$$] Another Big GE Stock Buyer: CenturyLink Unit Barrons.com
01:25PM  Assessing Incytes 3Q17 Product Portfolio Market Realist
12:32PM  Analysts Recommendations for Mylan Market Realist
12:18PM  After Irrational Fire Sale, Its Time to Buy the Dip in Merck & Co., Inc. Stock InvestorPlace
10:23AM  Examining Incytes Quarterly Revenue Trend Market Realist
08:21AM  3 Top Healthcare Stocks to Buy in January Motley Fool
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Jan-08-18 08:30AM  Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time GlobeNewswire
Jan-05-18 10:58PM  [$$] Bristol-Myers Squibb to Take $3 Billion Charge Related to Tax Overhaul The Wall Street Journal
07:18PM  [$$] Bristol-Myers Squibb to Take $3 Billion Charge Related to Tax Overhaul The Wall Street Journal
06:41PM  Bristol-Myers sees $3 billion tax hit in fourth quarter 2017 Reuters
06:04PM  Bristol-Myers sees $3 billion tax hit in fourth quarter 2017 Reuters
01:43PM  Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial Zacks
11:25AM  9 Stocks That Can Outperform As Bull Market Ages: Goldman Investopedia
Jan-04-18 04:46PM  [$$] Funding Snapshot: Personal Genome Diagnostics Raises $75 Million Series B The Wall Street Journal
Jan-03-18 11:27AM  5 Stocks Insiders and Hedge Funds Are Crazy About Insider Monkey
09:00AM  Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference Business Wire
07:35AM  Johnson & Johnsons Valuation in December 2017 Market Realist
07:30AM  EX-Dividend Schedule: Bristol-Myers Squibb Raised its Dividend by 2.6%; Will Trade Ex-Dividend on January 04, 2018 ACCESSWIRE
Jan-02-18 09:25AM  Should You Buy Bristol-Myers Squibb Stock in 2018? Motley Fool
08:57AM  4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio Zacks
Dec-29-17 11:18AM  Eli Lillys Valuation in December 2017 Market Realist
Dec-28-17 08:39AM  Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018? Zacks
07:31AM  How Is Johnson & Johnsons Infectious Disease Business Positioned? Market Realist
Dec-27-17 10:05AM  Read This Before Buying Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming $0.4 Dividend Simply Wall St.
06:00AM  4 Top Pharmaceutical Stocks for 2018 Investopedia
Dec-26-17 04:12PM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of Bristol-Myers Squibb Company Investors (BMY) Business Wire
08:00AM  Michael Farr: My top 10 stocks for 2018 CNBC
Dec-22-17 10:07AM  Cancer Space Update: FDA Approves Label Expansion of 4 Drugs Zacks
08:42AM  Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb Motley Fool
08:02AM  Pharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs Zacks
06:04AM  3 Promising Cancer Immunotherapies to Watch in 2018 Motley Fool
Dec-21-17 08:55PM  BMY INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Bristol-Myers Squibb Company Investors Business Wire
10:41AM  Aeterna Zentaris jumps on FDA approval, Honda bets on solid-state battery, Rolling Stone is sold Yahoo Finance Video
Dec-20-17 05:26PM  After Hitting Support, Vetr Issues Buy Rating On Bristol Myers Benzinga
03:28PM  Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease Business Wire
02:00PM  Exelixis' Cabometyx Takes Aim at Sutent in Kidney Cancer Motley Fool
09:25AM  Is It Time To Sell Bristol-Myers Squibb Company (NYSE:BMY) Based Off Its PE Ratio? Simply Wall St.
06:59AM  TARIS and Bristol-Myers Squibb Announce Clinical Trial Collaboration Business Wire
01:18AM  [$$] Apotex Founder Barry Sherman Was Driven, Generous...and Litigious The Wall Street Journal
Dec-19-17 09:05AM  Bristol-Myers Yervoy Gets Positive CHMP Opinion for Melanoma Zacks
09:00AM  Bristol-Myers Squibb to Announce Results for Fourth Quarter 2017 on February 5th Business Wire
Dec-18-17 10:30AM  Analysts Recommendations for Bristol-Myers Squibb Market Realist
09:01AM  What Analysts Expect for Bristol-Myers Squibb Market Realist
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaboration agreements with Portola Pharmaceuticals, Inc., Apexigen, Inc., and Nordic Bioscience; clinical research collaborations with Array BioPharma, Novartis, Clovis Oncology, Inc., and Daiichi Sankyo; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Samuels Theodore R. IIDirectorDec 15Buy62.304,000249,18722,000Dec 18 04:21 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerDec 12Sale63.245,300335,1729,251Dec 13 05:31 PM
LEUNG SANDRAEVP, General CounselDec 04Option Exercise22.14156,5823,466,725584,373Dec 05 06:15 PM
LEUNG SANDRAEVP, General CounselDec 04Sale63.37156,5829,922,601427,791Dec 05 06:15 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010267,770Dec 05 06:15 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494068,166Nov 03 04:32 PM
Caldarella Joseph CSVP & ControllerSep 06Sale60.009,340560,40046,297Sep 08 04:31 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,594038,811Sep 06 04:46 PM
Samuels Theodore R. IIDirectorAug 02Buy55.946,000335,62218,000Aug 03 05:08 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510028,751Aug 03 05:07 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMay 14Option Exercise0.0014,551014,551Jun 08 04:51 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400180,458May 09 04:32 PM
ANDREOTTI LAMBERTODirectorApr 07Sale53.2217,000904,791935,571Apr 10 05:09 PM
ANDREOTTI LAMBERTODirectorApr 06Sale53.2917,000905,964952,571Apr 10 05:09 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554044,125Apr 04 07:17 PM
ANDREOTTI LAMBERTODirectorMar 28Sale56.2017,000955,369969,112Mar 29 06:19 PM
ANDREOTTI LAMBERTODirectorMar 27Sale56.1417,000954,451986,112Mar 29 06:19 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 17Sale56.495,000282,47021,483Mar 21 04:35 PM
Caldarella Joseph CSVP & ControllerMar 15Sale57.298,096463,77955,637Mar 22 06:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 14Sale56.7515,000851,22026,483Mar 16 04:37 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0087,6040199,229Mar 14 08:32 PM
Blin EmmanuelSVP, Chief Strategy OfficerMar 10Option Exercise0.0013,275023,690Mar 14 08:32 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0066,7260346,770Mar 14 08:33 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0065,4240451,862Mar 14 08:33 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,7210119,772Mar 14 08:31 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0025,592035,898Mar 14 08:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0087,3240289,293Mar 14 08:31 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.0013,696041,215Mar 14 08:30 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00102,17401,060,105Mar 14 08:30 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0031,513052,546Mar 14 08:29 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0018,799073,284Mar 14 08:29 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0033,271051,898Mar 14 08:30 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0015,484068,911Mar 14 08:29 PM
LEUNG SANDRAEVP, General CounselMar 06Sale57.0292,4055,268,563395,658Mar 07 04:39 PM
LEUNG SANDRAEVP, General CounselMar 03Option Exercise27.01116,1003,135,861488,063Mar 07 04:39 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise27.0122,598610,372212,516Mar 01 04:47 PM
Samuels Theodore R. IIDirectorFeb 27Buy56.7712,000681,24012,000Mar 01 04:47 PM
ANDREOTTI LAMBERTODirectorJan 30Option Exercise27.01100,0002,701,000957,931Feb 01 04:43 PM